Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

223 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Tumor infiltrating lymphocytes (TILs) in triple negative breast cancer].
Abdullaeva SR, Semiglazova TY, Artemyeva AS, Zagoruiko VA, Kudriashova TI, Filatova LV, Semiglazov VV, Krivorotko PV, Semiglazov VF. Abdullaeva SR, et al. Among authors: semiglazov vf. Arkh Patol. 2024;86(3):5-11. doi: 10.17116/patol2024860315. Arkh Patol. 2024. PMID: 38881000 Russian.
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.
Dugo M, Huang CS, Egle D, Bermejo B, Zamagni C, Seitz RS, Nielsen TJ, Thill M, Antón-Torres A, Russo S, Ciruelos EM, Schweitzer BL, Ross DT, Galbardi B, Greil R, Semiglazov V, Gyorffy B, Colleoni M, Kelly CM, Mariani G, Del Mastro L, Blasi O, Callari M, Pusztai L, Valagussa P, Viale G, Gianni L, Bianchini G. Dugo M, et al. Clin Cancer Res. 2024 Nov 1;30(21):4900-4909. doi: 10.1158/1078-0432.CCR-24-0149. Clin Cancer Res. 2024. PMID: 39308141 Free PMC article. Clinical Trial.
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J; CLEOPATRA Study Group. Swain SM, et al. N Engl J Med. 2015 Feb 19;372(8):724-34. doi: 10.1056/NEJMoa1413513. N Engl J Med. 2015. PMID: 25693012 Free PMC article. Clinical Trial.
Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial.
Venet D, Rediti M, Maetens M, Fumagalli D, Brown DN, Majjaj S, Salgado R, Pusztai L, Harbeck N, El-Abed S, Wang Y, Saura C, Gomez H, Semiglazov VF, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart M, Loi S, Rothé F, Sotiriou C. Venet D, et al. Among authors: semiglazov vf. Clin Cancer Res. 2021 Oct 15;27(20):5607-5618. doi: 10.1158/1078-0432.CCR-21-1317. Epub 2021 Jul 28. Clin Cancer Res. 2021. PMID: 34321278
TiLoop Bra Assisted Breast Reconstruction - Our Experience.
Krivorotko PV, Pesotsky RS, Zernov KY, Zhiltsova EK, Tabagua TT, Bessonov AA, Komyahov AV, Nikolaev KS, Rychagov KY, Gigolaeva LP, Zirov KY, Aseeva ZA, Emelyanov AS, Enaldieva DA, Bondarchuk YI, Levchenko VE, Belyaev AM, Semiglazov VF. Krivorotko PV, et al. Among authors: semiglazov vf. Chirurgia (Bucur). 2021 Mar-Apr;116(2 Suppl):84-90. Chirurgia (Bucur). 2021. PMID: 33963697 Free article.
Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.
Baselga J, Manikhas A, Cortés J, Llombart A, Roman L, Semiglazov VF, Byakhov M, Lokanatha D, Forenza S, Goldfarb RH, Matera J, Azarnia N, Hudis CA, Rozencweig M. Baselga J, et al. Among authors: semiglazov vf. Ann Oncol. 2019 Jun 1;30(6):1017. doi: 10.1093/annonc/mdy529. Ann Oncol. 2019. PMID: 30624616 Free PMC article. No abstract available.
Regeneration and Cicatrization.
Pechersky AV, Pechersky VI, Shpilenya ES, Gaziev AH, Semiglazov VF. Pechersky AV, et al. Among authors: semiglazov vf. J Stem Cells. 2016;11(2):89-97. J Stem Cells. 2016. PMID: 28296867 Review.
223 results